Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DAVIS, J. D.
Right arrow Articles by PATTISON, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DAVIS, J. D.
Right arrow Articles by PATTISON, E. H.
(Chest. 1950;18:521-527.)
© 1950 American College of Chest Physicians

Tibione: Laboratory and Clinical Studies

J. DWIGHT DAVIS M.D., F.C.C.P.1; SOLOMON NETZER M.D., F.C.C.P.2; JOSEPH A. SCHWARTZ M.D., F.C.C.P.1; and ERIC H. PATTISON M.D.1

1 The Pulmonary Disease Service of the Birmingham Veterans Administration Hospital, Van Nuys, California, and San Fernando Veterans Administration Hospital, San Fernando, California.
2 Chief, Tuberculosis Service, San Fernando Veterans Administration Hospital, San Fernando, California., The Pulmonary Disease Service of the Birmingham Veterans Administration Hospital, Van Nuys, California, and San Fernando Veterans Administration Hospital, San Fernando, California.

1) Tibione is a drug of moderate toxicity.

2) The greatest toxic manifestations are gastro-intestinal disturbances which develop primarily during the third week and generally persist only a short time.

3) Other complications are dermatitis, anemia, and impaired hepatic function.

4) A decrease in cough and sputum, and a sense of well-being occur with tibione.

5) Tibione is a chemotherapeutic agent capable of conversion of the sputum.

6) X-ray film improvement after 120 days of tibione therapy has been noted. The improvement is not as marked as with streptomycin for a comparable period.

7) There has been demonstrated an acquired resistance of M. tuberculosis toward tibione.

8. Tibione should be administered only where adequate laboratory facilities are available so that frequent laboratory tests can be made.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1950 by the American College of Chest Physicians.